| |
[摘要]：Background: The epithelial-mesenchymal transition (EMT) is also involved in cancer progression and metastasis. The expression of mesenchymal marker genes might be associated with a more aggressive form of the disease. CDI46 is a marker of mesenchymal cells, a potentially metastasis-promoting cell adhesion molecule, and its expression has been described in various types of solid tumors. We, herein, evaluated the expression of CDI46 in patients with adenocarcinoma of the lung by using immunohistochemisny to clarify its clinical significance. Materials and Methods: Tumor specimens were collected from 183 consecutive patients who underwent complete resection far lung atlenocarcinoma from 2003 to 2007 in our Department. We analyzed the CDI46 expression levels in the primary lung adenocarcinoma by immunohistochemistry. Results: Positive expression of CDI46 was identified in 16 (8.7%) patients. A significant association was only observed between the CDI46 expression level and male patient gender (p=0.03); other factors were not associated with CDI46 expression. The 5-year overall survival (OS) rate in patients with tumors that were negative and positive for CDI46 expression was 84.4% and 50.0%, respectively (p<0.01). A positive CDI46 expression was found to be associated with the OS based on a univariate survival analysis (p=0.013). Conclusion: CDI46 expression was more frequently detected in males than in females. The positive expression of CDI46 was associated with a poorer OS according to the survival analysis. CDI46 may be a useful marker for predicting poor prognosis in patients with NSCLC following complete resection. |
|
